Matches in Wikidata for { <http://www.wikidata.org/entity/Q66397533> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q66397533 description "clinical trial" @default.
- Q66397533 description "ensayu clínicu" @default.
- Q66397533 description "klinisch onderzoek" @default.
- Q66397533 description "клінічне випробування" @default.
- Q66397533 name "To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer" @default.
- Q66397533 name "To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer" @default.
- Q66397533 type Item @default.
- Q66397533 label "To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer" @default.
- Q66397533 label "To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer" @default.
- Q66397533 prefLabel "To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer" @default.
- Q66397533 prefLabel "To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer" @default.
- Q66397533 P1132 Q66397533-CB0063D4-C219-4D1A-9C2B-2E6F87F98698 @default.
- Q66397533 P1476 Q66397533-6C27F6C4-3C9D-4A0D-BAC1-43414AE35240 @default.
- Q66397533 P17 Q66397533-4ACD0FFD-56FE-4BE5-931E-4B4E201F623A @default.
- Q66397533 P2899 Q66397533-77580523-152D-448C-A125-15B4DAE871ED @default.
- Q66397533 P3098 Q66397533-0EA275F5-CAE1-4986-8071-A4BC446F676A @default.
- Q66397533 P31 Q66397533-1FA40C39-4919-4202-8C54-44F47221DE16 @default.
- Q66397533 P4135 Q66397533-524DD761-C854-4765-88B3-E3C429AE7ECA @default.
- Q66397533 P4844 Q66397533-050286D1-9861-4EC1-8E3A-D287A7C3E271 @default.
- Q66397533 P4844 Q66397533-B9B5D3DC-C1CB-4D06-9CEE-27801E4ED3CF @default.
- Q66397533 P580 Q66397533-B5A1AEB2-F6C2-4B20-AE74-0AA7F49ED4D3 @default.
- Q66397533 P582 Q66397533-60E48DA0-7D4C-489A-B686-8FE3D1951B67 @default.
- Q66397533 P6099 Q66397533-D95DB460-FD42-4B73-B623-DC15D67FA60E @default.
- Q66397533 P8363 Q66397533-6E5B2DD2-BD8A-4837-9F59-9B0A21C32875 @default.
- Q66397533 P859 Q66397533-511021E0-F085-40FE-9F42-9D89911E4559 @default.
- Q66397533 P1132 "+182" @default.
- Q66397533 P1476 "An Open-Label, Multicenter, Randomized, Phase II Study to Evaluate the Efficacy and Safety of Two Combination Dose Regimens: Capecitabine + Epirubicin + Cyclophosphamide (CEX) Versus 5-FU + Epirubicin + Cyclophosphamide (FEC 100) as Neoadjuvant Therapy in Females Presenting With Operable Breast Cancer" @default.
- Q66397533 P17 Q142 @default.
- Q66397533 P2899 "+18" @default.
- Q66397533 P3098 "NCT02846428" @default.
- Q66397533 P31 Q30612 @default.
- Q66397533 P4135 "+70" @default.
- Q66397533 P4844 Q238512 @default.
- Q66397533 P4844 Q408524 @default.
- Q66397533 P580 "2004-03-01T00:00:00Z" @default.
- Q66397533 P582 "2011-12-01T00:00:00Z" @default.
- Q66397533 P6099 Q42824440 @default.
- Q66397533 P8363 Q78089383 @default.
- Q66397533 P859 Q212646 @default.